aHSP Antikörper

Produktnummer ABIN1387096

Produktdetails anti-aHSP Antikörper

Target: aHSP (alpha Hemoglobin Stabilizing Protein (aHSP))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser aHSP Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Kreuzreaktivität: Human

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human AHSP/ERAF

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
IHC-P 1:200-400
IF(IHC-P) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Details zu aHSP

Target: aHSP (alpha Hemoglobin Stabilizing Protein (aHSP))

Andere Bezeichnung: AHSP (aHSP Produkte)

Synonyme: AHSP antikoerper, ERAF antikoerper, EDRF antikoerper, Eraf antikoerper, alpha hemoglobin stabilizing protein antikoerper, alpha-hemoglobin-stabilizing protein-like antikoerper, AHSP antikoerper, Ahsp antikoerper, LOC100620111 antikoerper

Hintergrund:

Synonyms: AHSP, AHSP_HUMAN, Alpha hemoglobin stabilizing protein, Alpha-hemoglobin-stabilizing protein, EDRF, ERAF, Erythroid associated factor, Erythroid dferentiation associated factor, Erythroid dferentiation related factor, Erythroid dferentiation-related factor, Erythroid-associated factor.

Background: Act as a chaperone to prevent the harmful aggregation of alpha-hemoglobin during normal erythroid cell development. Specifically protects free alpha-hemoglobin from precipitation. It is predicted to modulate pathological states of alpha-hemoglobin excess such as beta-thalassemia.